Looker Benjamin (CIK 1859509) reported 10 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-18). Recent activity: Sell ESPR (11,824 shares), Sell ESPR (5,708 shares), Buy ESPR (300,840 shares), Sell ESPR (1,689 shares), Sell ESPR (6,517 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Legal Officer | Sell | 11,824 | $37,305 |
| 2026-03-18 | Esperion Therapeutics, Inc. (ESPR) | Chief Legal Officer | Sell | 5,708 | $15,412 |
| 2026-03-16 | Esperion Therapeutics, Inc. (ESPR) | Chief Legal Officer | Buy | 300,840 | $0 |
| 2026-01-21 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Sell | 1,689 | $4,864 |
| 2025-12-18 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Sell | 6,517 | $23,917 |
| 2025-10-20 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Sell | 1,248 | $3,270 |
| 2025-09-18 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Sell | 6,267 | $17,548 |
| 2025-07-18 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Sell | 1,304 | $1,474 |
| 2025-06-18 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Sell | 6,422 | $7,385 |
| 2025-03-17 | Esperion Therapeutics, Inc. (ESPR) | General Counsel | Buy | 224,000 | $0 |
Source: SEC Form 4 filings · as of 2026-06-18